Company Profile

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mankind Pharma has informed that the management and officials of the Company will participate in below conference and investor meetings: (i) Jefferies 5th Asia Forum/ Investor Conference - scheduled on 19th and 20th March 2024 in Hong Kong and (ii) meetings with various investors scheduled on 21st and 22nd March 2024 in Singapore.  No Unpublished Price Sensitive Information will be shared at the aforesaid conference/ investor meetings. 

The above information is a part of company’s filings submitted to BSE. 

Mankind Pharma is currently trading at Rs. 2165.60, up by 3.30 points or 0.15% from its previous closing of Rs. 2162.30 on the BSE.

The scrip opened at Rs. 2156.80 and has touched a high and low of Rs. 2195.95 and Rs. 2154.60 respectively. So far 1732 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 2297.00 on 08-Feb-2024 and a 52 week low of Rs. 1240.75 on 22-May-2023.

Last one week high and low of the scrip stood at Rs. 2200.25 and Rs. 2121.40 respectively. The current market cap of the company is Rs. 86619.24 crore.

The promoters holding in the company stood at 76.51%, while Institutions and Non-Institutions held 16.53% and 6.97% respectively.

Mankind Pharma has entered into an agreement with AstraZeneca Pharma India for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India. AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder (MAH) and import license. 

With an expansive distribution network including close to 16,000 field force and more than 13,000 stockists across India, Mankind Pharma has positioned itself as a leader in ensuring availability and access to quality pharmaceuticals across the country, including small towns and rural areas.

Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.

Rail Vikas Nigam has emerged as the Lowest Bidder (L1) from Central Railway for Signalling and Telecommunication work for provision of Automatic block signaling on Khapri- Sewagram Section of Nagpur Division.

NBCC’s wholly owned subsidiary -- HSCC (India) has bagged work orders worth Rs 367.92 crore from Medical Education & Ayush, Maharashtra, and Power Grid Corporation India. Medical Education & Ayush has awarded HSCC with six work contracts worth Rs 262.13 crore. HSCC has secured three work orders from Power Grid Corporation India, whose total value is Rs 105.79 crore.

Mankind Pharma has entered into an agreement with AstraZeneca Pharma India for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India. AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder (MAH) and import license. 

Venus Remedies has secured Good Manufacturing Practices (GMP) approval from the United Nations Children's Fund (UNICEF). This milestone achievement underscores Venus Remedies' dedication to delivering top-tier pharmaceutical solutions worldwide. The company’s manufacturing unit, located in Baddi, Himachal Pradesh, India, has been approved to supply UNICEF with Cephalosporin antibiotics for treating infections.

Genpharmasec has acquired 70% stake in Derren Healthcare. The objective of acquisition is to expand the activities of Genpharmasec and to make a foray in manufacturing of formulations.

British American Tobacco Plc is reportedly preparing to kick off a sale of part of its stake in ITC as soon as this week. The company has been speaking with Bank of America Corp. and Citigroup Inc. about a potential divestment of around $2 billion to $3 billion in ITC stock through block trades.

Mankind Pharma has entered into an agreement with AstraZeneca Pharma India for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India. AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder (MAH) and import license. 

With an expansive distribution network including close to 16,000 field force and more than 13,000 stockists across India, Mankind Pharma has positioned itself as a leader in ensuring availability and access to quality pharmaceuticals across the country, including small towns and rural areas.

Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.